News|Articles|July 1, 2025

Allergy Month in Review: June 2025

This month in review captures 5 allergy news in June, from FDA approvals to phase 3 data.

In this month’s allergy review, several key advances indicate treatment progress. The US Food and Drug Administration (FDA) accepted the new drug application (NDA) for Anaphylm, a needle-free epinephrine film, and approved garadacimab-gxii (ANDEMBRY) for hereditary angioedema (HAE) prevention. LYR-210, a six-month nasal implant, showed strong phase 3 results for chronic rhinosinusitis (CRS).

Related to this article

October 7th, 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

October 6th, 2026

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

October 6th, 2026

Top Reason for Leaving HAE Attacks Untreated, Survey Finds

Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.

October 3rd, 2026

Q3 2026 Recap: Allergy News and Updates

Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.

October 1st, 2026

4 Allergy Headlines You Missed in September 2026

From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.